<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03852498</url>
  </required_header>
  <id_info>
    <org_study_id>ALD-104</org_study_id>
    <nct_id>NCT03852498</nct_id>
  </id_info>
  <brief_title>Clinical Study to Assess the Efficacy and Safety of Gene Therapy for the Treatment of Cerebral Adrenoleukodystrophy (CALD)</brief_title>
  <official_title>A Phase 3 Study of Lenti-D Drug Product After Myeloablative Conditioning Using Busulfan and Fludarabine in Subjects ≤17 Years of Age With Cerebral Adrenoleukodystrophy (CALD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>bluebird bio</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>bluebird bio</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study ALD-104 is an international, non-randomized, open-label, multi-site study in male
      subjects (≤17 years of age at enrollment) with cerebral adrenoleukodystrophy (CALD).
      Approximately 35 subjects will be infused with Lenti-D Drug Product after myeloablative
      conditioning with busulfan and fludarabine.

      This trial will evaluate the efficacy and safety of autologous CD34+ hematopoietic stem
      cells, transduced ex-vivo with Lenti-D lentiviral vector, for the treatment of CALD. A
      subject's blood stem cells will be collected and modified (transduced) using the Lenti-D
      lentiviral vector encoding human adrenoleukodystrophy protein. After modification
      (transduction) with the Lenti-D lentiviral vector, the cells will be transplanted back into
      the subject following myeloablative conditioning.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 24, 2019</start_date>
  <completion_date type="Anticipated">February 2024</completion_date>
  <primary_completion_date type="Anticipated">February 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of subjects who are alive and have none of the 6 major functional disabilities (MFDs) at Month 24 (i.e. Month 24 MFD-free survival).</measure>
    <time_frame>At 24 months (±1 months) post-transplant</time_frame>
    <description>MFDs are:
loss of communication
cortical blindness
tube feeding
total incontinence
wheelchair dependence
complete loss of voluntary movement</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The proportion of subjects with neutrophil engraftment after drug product infusion.</measure>
    <time_frame>At 42 days post-drug product infusion</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects without gadolinium enhancement on MRI (i.e., GdE-) at Month 24.</measure>
    <time_frame>At 24 months (±1 months) post-transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Value and change in total Neurologic Function Score (NFS) from Baseline to protocol scheduled visits.</measure>
    <time_frame>From Baseline through study completion, an average of 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MFD-free survival over time.</measure>
    <time_frame>From drug product infusion through study completion, an average of 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival.</measure>
    <time_frame>From drug product infusion through study completion, an average of 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Detectable vector copy number (VCN) in peripheral blood cells by Month 6.</measure>
    <time_frame>Up to 6 months (+/- 14 days) post-transplant</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">35</enrollment>
  <condition>Cerebral Adrenoleukodystrophy (CALD)</condition>
  <arm_group>
    <arm_group_label>Lenti-D Drug Product</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenti-D; elivaldogene autotemcel</intervention_name>
    <description>Lenti-D Drug Product (autologous CD34+ cell-enriched population that contains cells transduced with Lenti-D lentiviral vector that encodes an ABCD1 cDNA for human adrenoleukodystrophy protein, suspended in a cryopreservation solution) is administered intravenously. Lenti-D Drug Product is administered by IV infusion following myeloablative conditioning with busulfan and fludarabine.</description>
    <arm_group_label>Lenti-D Drug Product</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Informed consent is obtained from a competent custodial parent or guardian with legal
             capacity to execute a local IRB/IEC approved consent. Informed assent will be sought
             from capable subjects, in accordance with the directive of the IRB/IEC and with local
             requirements.

          2. Males aged 17 years and younger, at the time of parental/guardian consent and, where
             appropriate, subject assent.

          3. Active cerebral ALD as defined by:

               1. Elevated very long chain fatty acids (VLCFA) values, and

               2. Active central nervous system (CNS) disease established by central radiographic
                  review of brain MRI demonstrating

             i. Loes score between 0.5 and 9 (inclusive) on the 34-point scale, and ii. Gadolinium
             enhancement on MRI of demyelinating lesions.

          4. Neurologic Function Score (NFS) ≤1.

        Exclusion Criteria:

          1. Prior receipt of an allogeneic transplant or gene therapy.

          2. Use of statins, Lorenzo's Oil, or dietary regimens used to lower VLCFA levels. Note:
             subjects must discontinue use of these medications at time of consent.

          3. Receipt of an investigational study drug or procedure within 3 months before Screening
             that might confound study outcomes. Use of investigational study drugs is prohibited
             throughout the course of the study.

          4. Any conditions that make it impossible to perform MRI studies (including allergies to
             anesthetics or contrast agents).

          5. Hematological compromise as evidenced by:

               1. Peripheral blood ANC count &lt;1500 cells/mm3, and either

               2. Platelet count &lt;100,000 cells/mm3, or

               3. Hemoglobin &lt;10 g/dL.

          6. Hepatic compromise as evidenced by:

               1. Aspartate transaminase (AST) value &gt;2.5 × ULN

               2. Alanine transaminase (ALT) value &gt;2.5 × ULN

               3. Total bilirubin value &gt;3.0 mg/dL, except if there is a diagnosis of Gilbert's
                  Syndrome and the subject is otherwise stable

          7. Baseline estimated glomerular filtration rate &lt;70 mL/min/1.73 m2

          8. Cardiac compromise as evidenced by left ventricular ejection fraction &lt;40%

          9. Immediate family member with a known or suspected Familial Cancer Syndrome

         10. Clinically significant uncontrolled, active bacterial, viral, fungal, parasitic, or
             prion associated infection.

         11. Positive for HIV, hepatitis B or C virus, or human T lymphotrophic virus 1 (HTLV-1)

         12. Any clinically significant cardiovascular, hematological, or pulmonary disease, or
             other disease or condition that would be contraindicated for any of the other study
             procedures.

         13. Absence of adequate contraception for fertile subjects.

         14. Any contraindications to the use of G-CSF or plerixafor during the mobilization of
             hematopoietic stem cells, and any contraindications to the use of busulfan or
             fludarabine, including known hypersensitivity to the active substances or to any of
             the excipients in their formulations.

         15. Known hypersensitivity to protamine sulfate.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew Dietz, MD</last_name>
    <role>Study Director</role>
    <affiliation>bluebird bio, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>bluebird bio</last_name>
    <phone>(339) 499-9300</phone>
    <email>clinicaltrials@bluebirdbio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Lucile Packard Children's Hospital</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kyle Kovtun</last_name>
      <phone>415-347-0135</phone>
      <email>kyle.kovtun@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>Ami Shah, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Boston Children's Hospital/Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Colleen Dansereau</last_name>
      <phone>617-919-7008</phone>
      <email>Colleen.Dansereau@childrens.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Christine Duncan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Florian Eichler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ashish Gupta, MD</last_name>
      <email>gupta461@umn.edu</email>
    </contact>
    <contact_backup>
      <last_name>Troy Lund, MD</last_name>
      <email>lundx072@umn.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Paul Orchard, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Robert Debré</name>
      <address>
        <city>Paris</city>
        <zip>75019</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Hugues Dalle, MD, PhD</last_name>
      <phone>+33 (0)1.40.03.53.88</phone>
      <email>jean-hugues.dalle@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Jean-Hugues Dalle, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Pediatrico Bambino Gesù</name>
      <address>
        <city>Rome</city>
        <zip>00165</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Franco Locatelli, MD</last_name>
      <phone>+39 06 68592129</phone>
      <email>franco.locatelli@opbg.org</email>
    </contact>
    <investigator>
      <last_name>Franco Locatelli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UCL-ICH/Great Ormond Street Hospital</name>
      <address>
        <city>London</city>
        <zip>WC1N3JH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lynsey Hart</last_name>
      <email>lynsey.hart@ucl.ac.uk</email>
    </contact>
    <contact_backup>
      <last_name>Camilla Duran-Person</last_name>
      <email>Camilla.Duran_Persson@gosh.nhs.uk</email>
    </contact_backup>
    <investigator>
      <last_name>Adrian Thrasher, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Robert Chiesa, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
    <country>Italy</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>February 13, 2019</study_first_submitted>
  <study_first_submitted_qc>February 21, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 25, 2019</study_first_posted>
  <last_update_submitted>July 17, 2020</last_update_submitted>
  <last_update_submitted_qc>July 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Adrenoleukodystrophy</keyword>
  <keyword>X-linked adrenoleukodystrophy</keyword>
  <keyword>Gene therapy</keyword>
  <keyword>Hematopoietic stem cell</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adrenoleukodystrophy</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

